Advanced search
Publication Cover
Cancer Investigation Volume 21, 2003 - Issue 2
Submit an article Journal homepage
48
Views
17
CrossRef citations to date
0
Altmetric
Original

Combination Chemotherapy with Gemcitabine and Vinorelbine in the Treatment of Patients with Relapsed or Refractory Small Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network

ORIGINAL ARTICLE

John D. Hainsworth M.D. Tennessee Oncology, PLLC, Nashville, Tennessee, USA
,
Howard A. Burris III M.D. Tennessee Oncology, PLLC, Nashville, Tennessee, USA
,
Joan B. Erland C.C.R.P. The Sarah Cannon Cancer Center, Nashville, Tennessee, USA
,
Margaret Baker C.R.A. The Sarah Cannon Cancer Center, Nashville, Tennessee, USA
,
Daniel C. Scullin Jr. M.D. Consultants in Blood Disorders & Cancer, Louisville, Kentucky, USA
,
Don W. Shaffer M.D., F.A.C.P. Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, USA
&
F. Anthony Greco M.D. Tennessee Oncology, PLLC, Nashville, Tennessee, USA
 show all
Pages 193-199 | Published online: 25 Mar 2003

References

  • Shepherd F.A., Evans W.K., MacCormack R., et al. Cyclophosphamide, doxorubicin and vincristine in etoposide and cisplatin-resistant small cell lung cancer. Cancer Treat. Rep. 1987; 71: 941–944
  • Sculier J.P., Klastersky J., Libert P., et al. A phase II study evaluating CAV; (cyclophosphamide, adriamycin, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small cell lung cancer. Lung Cancer 1990; 6: 110–118
  • Kubota K., Nishiwaki Y., Kokinuma R., et al. Dose-intensive weekly chemotherapy for treatment of relapsed small cell lung cancer. J. Clin. Oncol. 1997; 15: 292–296
  • Van Pawel J., Schiller J.H., Shepherd F.A., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small cell lung cancer. J. Clin. Oncol. 1999; 17: 658–667
  • Ettinger D.S., Finkelstein D.M., Sarma R.P., et al. Phase II study of paclitaxel in patients with extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 1995; 13: 1430–1435
  • Masuda N., Fukuoka M., Kusunoki Y., et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J. Clin. Oncol. 1992; 10: 1225–1229
  • Furuse K., Kubota K., Kawahara M., et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology 1996; 53: 169–172
  • Cormier Y., Eisenhauer E., Muldal A., et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer: a study of The National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol. 1994; 5: 283–285
  • Herbst R.S., Khuri F.R., Jung M., et al. Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 1999; 18: 462a, (Abstr)
  • Hirsch V., Ayoub J., Cormier Y., Kerby W., Iglesias J. Phase II multicenter trial with gemcitabine and vinorelbine in patients with advanced (stage IIIB and IV) non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 1999; 18: 508a, (Abstr)
  • Hainsworth J.D., Burris H.A., Litchy S., et al. Gemcitabine and vinorelbine in the second-line treatment of non-small cell lung cancer: a Minnie Pearl Cancer Research Network phase II trial. Cancer 2000; 88: 1353–1358
  • Lilenbaum R., Cano R., Schwartz M., et al. Gemcitabine and vinorelbine in advanced non-small cell lung carcinoma: a phase II study. Cancer 2000; 88: 557–562
  • Bajetta E., Stani S.C., DeCandis D., et al. Gemcitabine plus vinorelbine as first-line chemotherapy in advanced non-small cell lung carcinoma: a phase II trial. Cancer 2000; 89: 763–768
  • Lorusso V., Carpagnano F., Frasci G., et al. Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small cell lung cancer. J. Clin. Oncol. 2000; 18: 405–411
  • Frasci G., Lorusso V., Panza N., et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J. Clin. Oncol. 2000; 18: 2529–2536
  • Gridelli C., Frontini L., Perrone F., et al. Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Br. J. Cancer 2000; 83: 707–714
  • Kaplan Z.L., Meier P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.